DuPont Merck claims these findings do not rule out plans to conduct vertical transmission studies where dosing would occur late in the third trimester. Meanwhile the expanded access program for efavirenz was enlarged this winter to allow enrollment for anyone who has had a CD4 count below 400 at any time and is unable to assemble an effective treatment combination from FDA-approved drugs. 1998 - Treatment Issues. Reproduced with permission. Inc. All rights reserved.
Noncommercial reproduction is encouraged.
Subscription lists are kept confidential. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only.